Dr. Edward L. Lain, M.D.

Medicare patients and services

Medicare patients, 2024

575

Services billed

9,719

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 29 companies reported 555 payments worth $629,999 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 35 industry-funded studies in 2025, from 13 companies. The companies reported $1,018,334 in research payments for these studies, mostly to the institutions running them.

• A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
  AbbVie Inc. · Completed · NCT06834789
• A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence
  AbbVie Inc. · Completed · NCT06387394
• M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study
  AbbVie Inc.
• A Multi-Site Study to Assess the Efficacy and Tolerability Of Exosomes in Females with Moderate to Severe Overall Facial Photodamage
  AbbVie Inc.
• C24-AD101 - A Multi-Site Study to Assess the Efficacy and Tolerability Of Exosomes in Females with Moderate to Severe Overall Facial Photodamage
  AbbVie Inc.
• Open-label phase i study to evaluate the pharmacokinetics of 5-aminolevulinic acid and protoporphyrin ix in human plasma under maximal use conditions after topical application of 3 tubes of BF-200 ala to a treatment f…
  Biofrontera Inc.
• [Trial of device that is not approved or cleared by the U.S. FDA]
  AbbVie Inc. · Withheld · NCT07215247
• An open label study evaluating the safety, tolerability and efficacy of trichostatin a in patients with mild to severe onychomycosis
  Vanda Pharmaceuticals Inc.
• A phase 3 randomized doubleblind 52WEEK placebocontrolled multicenter study with a doubleblind 52WEEK extension period with randomized dose updose down titration investigating the efficacy safety and tolerability of r…
  Pfizer Inc.
• A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients wi…
  Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Dermatology clinicians in Austin

• Ammar M. Ahmed, MD
• Helyn Alvarez, MD
• Jennifer Aranda, MD
• Sascha E. Asghari, LHR PROFESSIONAL TEC
• Maria Batchinsky, MD
• Roopal K. Bhatt, MD
• Jonathan A. Bielfield, DO
• Jeffrey M. Boos, M.D.